An exploratory study examining how nano-liquid chromatography–mass spectrometry and phosphoproteomics can differentiate patients with advanced fibrosis and higher percentage collagen in non-alcoholic fatty liver disease-Reference-Cited by-同舟云学术

An exploratory study examining how nano-liquid chromatography–mass spectrometry and phosphoproteomics can differentiate patients with advanced fibrosis and higher percentage collagen in non-alcoholic fatty liver disease

Published:2018-09-12 Issue:1 Volume:16 Page:
ISSN:1741-7015
Container-title:BMC Medicine
language:en
Short-container-title:BMC Med

Author:

Younossi Zobair M.,Karrar Azza,Pierobon Mariaelena,Birerdinc Aybike,Stepanova Maria,Abdelatif Dinan,Younoszai Zahra,Jeffers Thomas,Felix Sean,Jeiran Kianoush,Hodge Alex,Zhou Weidong,Monge Fanny,Alaparthi Lakshmi,Chandhoke Vikas,Goodman Zachary D.,Petricoin Emanuel F.

Publisher

Springer Science and Business Media LLC

Subject

General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12916-018-1136-1.pdf

Reference57 articles.

1. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84.

2. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–9.

3. Younossi ZM, Blissett D, Blissett R, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64:1577–86.

4. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–23.

5. Stepanova M, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol. 2012;10:646–50.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HDAC6 inhibitor ACY-1215 protects from nonalcoholic fatty liver disease via inhibiting CD14/TLR4/MyD88/MAPK/NFκB signal pathway;Heliyon;2024-07

2. Idiopathic pulmonary fibrosis-specific Bayesian network integrating extracellular vesicle proteome and clinical information;Scientific Reports;2024-01-15

3. HADHA alleviates hepatic steatosis and oxidative stress in NAFLD via inactivation of the MKK3/MAPK pathway;Molecular Biology Reports;2022-11-14

4. Advance of Serum Biomarkers and Combined Diagnostic Panels in Nonalcoholic Fatty Liver Disease;Disease Markers;2022-06-29

5. Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches;Diagnostics;2022-02-04